Evidence map›Paper›PMID 24381528›Full record

ArticleCurrent neuropharmacology2013

Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century.

Wing-Hin Lee, Ching-Yee Loo, Mary Bebawy, Frederick Luk, Rebecca S Mason, Ramin Rohanizadeh

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current neuropharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 167 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
167citing papers in PubMed, 3 pooled it
8.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

167 citing papers in PubMed, 3 syntheses or guidelines pooled it, 528 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

107 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Wing-Hin LeeAdvanced Drug Delivery Group, Faculty of Pharmacy, University of Sydney, NSW 2006, Australia;
Ching-Yee LooAdvanced Drug Delivery Group, Faculty of Pharmacy, University of Sydney, NSW 2006, Australia;
Mary BebawySchool of Pharmacy, Graduate School of Health, University of Technology Sydney PO Box 123 Broadway, NSW 2007, Australia;
Frederick LukSchool of Pharmacy, Graduate School of Health, University of Technology Sydney PO Box 123 Broadway, NSW 2007, Australia;
Rebecca S MasonPhysiology and Bosch Institute, University of Sydney, NSW 2006, Australia.
Ramin RohanizadehAdvanced Drug Delivery Group, Faculty of Pharmacy, University of Sydney, NSW 2006, Australia;
University of Sydney · AUUniversity of Technology Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Curcumin (diferuloylmethane), a polyphenol extracted from the plant Curcuma longa, is widely used in Southeast Asia, China and India in food preparation and for medicinal purposes. Since the second half of the last century, this traditional medicine has attracted the attention of scientists from multiple disciplines to elucidate its pharmacological properties. Of significant interest is curcumin's role to treat neurodegenerative diseases including Alzheimer's disease (AD), and Parkinson's disease (PD) and malignancy. These diseases all share an inflammatory basis, involving increased cellular reactive oxygen species (ROS) accumulation and oxidative damage to lipids, nucleic acids and proteins. The therapeutic benefits of curcumin for these neurodegenerative diseases appear multifactorial via regulation of transcription factors, cytokines and enzymes associated with (Nuclear factor kappa beta) NFκB activity. This review describes the historical use of curcumin in medicine, its chemistry, stability and biological activities, including curcumin's anti-cancer, anti-microbial, anti-oxidant, and anti-inflammatory properties. The review further discusses the pharmacology of curcumin and provides new perspectives on its therapeutic potential and limitations. Especially, the review focuses in detail on the effectiveness of curcumin and its mechanism of actions in treating neurodegenerative diseases such as Alzheimer's and Parkinson's diseases and brain malignancies.

Indexed as

Alzheimeranti-inflammatoryanti-oxidantCurcuminglioblastomaParkinsonreactive oxygen species

Identifiers

PMID24381528
PMCPMC3744901
OpenAlexW2001955314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.